161 related articles for article (PubMed ID: 6226871)
1. [Gestagen therapy of breast cancer. Effect of high doses on the blood coagulation system].
Schenk H; Fereberger W
MMW Munch Med Wochenschr; 1983 Oct; 125(40):875-6. PubMed ID: 6226871
[No Abstract] [Full Text] [Related]
2. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
Possinger K; Wagner H; Langecker P; Schmid L; Willich S; Wilmanns W
Fortschr Med; 1987 Jul; 105(22):421-4. PubMed ID: 2958397
[No Abstract] [Full Text] [Related]
3. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
[TBL] [Abstract][Full Text] [Related]
4. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
Brockerhoff P; Grill HJ; Holzer A; Kreienberg R; Pollow K; Schicketanz KH; Schwarz V; Rathgen GH
Gynakol Rundsch; 1991; 31(4):189-200. PubMed ID: 1839014
[TBL] [Abstract][Full Text] [Related]
5. [High-dose gestagen therapy in breast cancer].
Beaufort F; Fereberger W
Wien Med Wochenschr; 1983 Apr; 133(7):169-73. PubMed ID: 6223450
[TBL] [Abstract][Full Text] [Related]
6. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
[TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
8. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
Flamm J; Spona J
Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
[TBL] [Abstract][Full Text] [Related]
9. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
10. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
[TBL] [Abstract][Full Text] [Related]
11. [High-dose gestagen therapy with medroxyprogesterone acetate in metastasizing breast carcinoma].
Bastert G; Michel RT
Med Welt; 1983 Mar; 34(12):378-82. PubMed ID: 6222235
[No Abstract] [Full Text] [Related]
12. [Hormonal control of disseminated breast cancer].
Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu
Sov Med; 1990; (6):94-7. PubMed ID: 2144368
[No Abstract] [Full Text] [Related]
13. Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study.
Tan YO; Hendrickson C; McWhirter K; Kohler M; Hannigan JF; Carlson RW
Cancer Treat Rep; 1987 Oct; 71(10):969-70. PubMed ID: 2958131
[No Abstract] [Full Text] [Related]
14. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
[No Abstract] [Full Text] [Related]
15. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
[TBL] [Abstract][Full Text] [Related]
16. [Histochemical and biochemical assays of estrogen receptors in breast cancer and significance of endocrine therapy].
Tominaga T
Gan No Rinsho; 1983 May; 29(6):628-31. PubMed ID: 6308307
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I).
Focan C; Baudoux A; Beauduin M; Bunescu U; Dehasque N; Dewasch L; Lobelle JP; Longeval E; Majois F; Mazy V
Acta Oncol; 1989; 28(2):237-40. PubMed ID: 2525397
[TBL] [Abstract][Full Text] [Related]
18. Depot medroxyprogesterone and breast cancer.
Day BJ; McCallum AB; Zambrano D; Tong DD
N Z Med J; 1990 Jul; 103(893):327-8. PubMed ID: 2142520
[No Abstract] [Full Text] [Related]
19. [A case of phlebothrombosis of lower extremity and pulmonary embolism due to progesterone].
Okada Y; Horikawa K
Kokyu To Junkan; 1992 Aug; 40(8):819-22. PubMed ID: 1388285
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with progestins and tamoxifen in advanced breast cancer: A preliminary report.
Trodella L; Ausilli-Cefaro GP; Turriziani A; Saccheri S; Venturo I; Minotti G
Am J Clin Oncol; 1982 Oct; 5(5):495-9. PubMed ID: 6217741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
